Indaptus Therapeutics, Inc. (INDP) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $1.33M; Additional Paid in CapitalUSD $95.66M; Retained Earnings (Accumulated Deficit)USD $-85.62M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $1.13M; Additional Paid in CapitalUSD $83.94M; Retained Earnings (Accumulated Deficit)USD $-83.83M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $10.00K; Common Stock, Value, IssuedUSD $21.67K; Additional Paid in CapitalUSD $84.41M; Retained Earnings (Accumulated Deficit)USD $-81.29M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $16.42K; Additional Paid in CapitalUSD $77.76M; Retained Earnings (Accumulated Deficit)USD $-73.18M.
Indaptus Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.33M | $95.66M | $-85.62M | $11.37M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $1.13M | $83.94M | $-83.83M | $1.25M | (m) | 3 month · $410.15K | (m) | (m) | (m) |
| 2025-12-31 | $10.00K | $21.67K | $84.41M | $-81.29M | $3.15M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $16.42K | $77.76M | $-73.18M | $4.61M | 3 month · $150.61K | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $6.05K | $68.52M | $-70.20M | $-1.67M | 3 month · $180.76K | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $160.34K | $67.61M | $-64.97M | $2.80M | 3 month · $240.89K | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $4.29K | $64.38M | $-60.44M | $3.94M | 12 month · $2.31M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $101.97K | $62.21M | $-56.31M | $6.00M | 3 month · $444.18K | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $85.53K | $59.32M | $-53.24M | $6.17M | 3 month · $782.85K | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $85.39K | $58.50M | $-49.22M | $9.36M | 3 month · $774.69K | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $84.01K | $57.41M | $-45.42M | $12.08M | 12 month · $2.97M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $84.01K | $56.66M | $-41.41M | $15.33M | 3 month · $764.80K | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $84.01K | $55.90M | $-37.49M | $18.63M | 3 month · $728.47K | (m) | (m) | $134.16K | (m) |
| 2023-03-31 | (m) | $84.01K | $55.17M | $-34.25M | $21.19M | 3 month · $727.14K | (m) | (m) | $177.46K | (m) |
| 2022-12-31 | (m) | $84.01K | $54.44M | $-29.99M | $24.63M | 12 month · $2.96M | (m) | (m) | $96.43K | (m) |
| 2022-09-30 | (m) | $82.59K | $53.81M | $-26.34M | $27.57M | 3 month · $584.04K | (m) | (m) | $15.13K | (m) |
| 2022-06-30 | (m) | $82.59K | $53.22M | $-22.87M | $30.41M | 3 month · $904.39K | (m) | (m) | $-26.94K | (m) |
| 2022-03-31 | (m) | $82.59K | $52.32M | $-19.04M | $33.36M | 3 month · $831.18K | (m) | (m) | $-9.22K | (m) |
| 2021-12-31 | (m) | $82.59K | $51.49M | $-15.67M | $35.90M | 12 month · $1.51M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $81.33K | (m) | $-12.45M | $38.08M | 3 month · $795.34K | (m) | $50.45M | (m) | (m) |
| 2021-06-30 | (m) | $727.00K | (m) | $-215.21M | $-1.32M | 3 month · $20.67K 6 month · $208.00K | (m) | $228.42M | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-829.68K | 3 month · $20.45K | (m) | (m) | (m) | (m) |
| 2020-12-31 | $8.36K | $19.45K | $7.69M | $-7.96M | $-237.70K | 12 month · $139.96K | (m) | $7.69M | (m) | 12 month · $3.96K |
| 2020-09-30 | (m) | (m) | (m) | (m) | $513.00 | 3 month · $39.21K | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $2.02M | 3 month · $38.78K 6 month · $856.00K | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $2.69M | 3 month · $38.88K | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $3.21M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |